Effects of lixisenatide on gastric emptying in Japanese patients with type 2 diabetes

Effects of lixisenatide on gastric emptying in Japanese patients with type 2 diabetes - Lixisenatide on gastric emptying

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039400

Enrollment

Registered

2020-02-05

Start date

2014-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

Lixisenatide therapy is initiated at 10 micro g daily, and the dose is increased to 20 micro g daily after 1 week.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T2DM

Exclusion criteria

Exclusion criteria: Patients who are judged by investigators to be inappropriate for inclusion in this study.

Design outcomes

Primary

Measure	Time frame
Changes of the half gastric emptying time (T1/2) and the lag phase (Tlag) before and after lixisenatide treatment	—

Countries

Japan

Contacts

Public ContactYoshio Nagai

St. Marianna University School of Medicine Division of Metabolism and Endocrinology, Department of Internal Medicine

ynagai@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026